Enveric Biosciences — Third Quarter 2026 Earnings Summary

Financial Performance:

• Net loss attributable to stockholders was $2.5 million for the quarter ended September 30, 2026, compared to $3.4 million for the same period in 2025.
• Basic and diluted loss per share was $0.57 for the quarter ended September 30, 2026, compared to $10.81 for the quarter ended September 30, 2025.
• The 2025 net loss included a $1.5 million deemed dividend on the inducement of warrants, which did not recur in 2026.
• Net non-cash expense was $0.2 million for the quarter ended September 30, 2026, compared to $0.1 million in the prior year period.
• Cash-on-hand totaled $5.6 million as of September 30, 2026.
• No revenue, gross profit, operating expenses, or debt figures were disclosed in the release.

Guidance and Future Outlook:

• The Company is advancing final IND-enabling activities to support a planned IND application for EB-003.
• Management intends to initiate a first-in-human Phase 1 clinical trial for EB-003 following the IND submission.
• The Company aims to develop EB-003 as a differentiated treatment for psychiatric and neurological disorders with the potential to support a simpler outpatient treatment model.

Business Segments and Product Lines:

• EB-003 Development:
  • Completed IND-enabling absorption and metabolic studies with favorable findings supporting potential for reduced drug-drug interactions.
  • Reported preclinical qEEG results demonstrating brain penetration and a pattern of brain activity distinct from dimethyltryptamine (DMT).
  • Reported in vitro mechanistic studies using GloSensor™ and BRET platforms supporting EB-003's predicted non-hallucinogenic profile.
  • qEEG data supports its evaluation as a potential pharmacodynamic biomarker to connect drug exposure with brain activity and guide dose selection.
• EVM401 Series:
  • Secured a U.S. patent allowance for next-generation, non-hallucinogenic mescaline derivatives.
• Regulatory Environment:
  • Supported the FDA release of finalized guidance for clinical investigations of psychedelic and psychedelic-inspired therapeutics.

Market and Competitive Landscape:

• No specific market share, competitor names, or market size data were provided.
• The Company positions EB-003 to offer advantages in clinical development and broader patient access compared to hallucinogenic therapies.

Risks and Challenges:

• Forward-looking statements highlight risks including the ability to finalize and submit an IND application, carry out successful clinical programs, and obtain necessary governmental approvals.
• Risks include the potential inability to establish product efficacy or safety, secure future funding, scale-up manufacturing, or retain key personnel.
• The Company notes the risk of failing to continue as a going concern.

Management Commentary and Tone:

• CEO Joseph Tucker, Ph.D., expressed confidence that recent data strengthens the foundation for advancing EB-003 toward clinical development.
• Management highlighted that independent assay platforms and ADMET studies provide complementary evidence of EB-003's differentiated profile.
• The tone is optimistic regarding the potential for EB-003 to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.

Other Key Points:

• Enveric Biosciences is a biotechnology company focused on next-generation, small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders.
• EB-003 is the Company's lead candidate, designed to selectively engage both 5-HT2A and 5-HT1B receptors.
• Investor and media relations are handled by Tiberend Strategic Advisors, Inc.